ArticleGastro hep advances2026
Progression of Metabolic Dysfunction-Associated Steatohepatitis in US Adults Using Linked Records and Claims.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Metabolic dysfunction-associated steatohepatitis (MASH) affects approximately 5% of adults globally and, without effective treatment, may progress to end-stage liver disease (ESLD), including compensated cirrhosis, decompensated cirrhosis (DC), hepatocellular carcinoma, and liver transplantation. Using real-world data, this study characterized the natural history and health-care impact of MASH among US adults. Methods: A retrospective cohort study was conducted using Optum's deidentified Market Clarity Data (January 2021-March 2024). Noninvasive test (NIT) use at diagnosis (days 0-30) and during follow-up was described. Predictors of progression were estimated with modified Poisson regression, time to first ESLD was assessed with Cox models, and health-care resource utilization (HCRU) and costs with multivariable regression. Results: Among 49,983 patients with MASH, 16,359 (32.7%) had ESLD at baseline (compensated cirrhosis 3965; DC 11,406; hepatocellular carcinoma 514; liver transplantation 474). Of the 33,624 without baseline ESLD, 15.9% progressed; median time to first ESLD event was 10.6 months (interquartile range: 3.8-19.7), with DC the most frequent first event. Around diagnosis, 3771 patients (7.5%) underwent ≥1 NIT or imaging test, slightly higher with baseline ESLD than without (8.1% vs 7.3%); NIT/imaging use increased during follow-up. Older age, hypertension, type 2 diabetes, cardiovascular disease, sleep apnea, smoking, and thyroid disease were associated with higher progression risk. Patients who progressed had higher HCRU and costs than those who did not progress. Conclusion: In this large US cohort, progression from MASH to ESLD was associated with high HCRU and costs, particularly among patients with ESLD or subsequent progression. These findings highlight the need for earlier risk stratification and targeted care to mitigate burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.